세계의 특발성 혈소판 감소성 자반증 치료제 시장 예측 : 제품별, 치료 유형별, 투여 방법별, 유통 채널별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Idiopathic Thrombocytopenic Purpura Therapeutics Market is accounted for $649.1 million in 2023 and is expected to reach $1045.0 million by 2030 growing at a CAGR of 7.04% during the forecast period. Idiopathic Thrombocytopenic Purpura (ITP) is a disorder characterized by a low platelet count in the blood (thrombocytopenia) due to the immune system mistakenly attacking and destroying platelets. Platelets are crucial for blood clotting, and a reduced platelet count can lead to abnormal bleeding or bruising. Patients are at risk of bleeding complications, so therapies may include platelet transfusions or medications to promote clotting and prevent bleeding episodes.

According to WebMD LLC, in 2022, ITP affected adults at roughly 66 cases per 1,000,000 per year. Children's incidence is estimated to be 50 cases per 1,000,000 per year on average, and about 10 new instances of chronic refractory ITP are reported each year per million people.

Market Dynamics:

Driver:

Rising demand for combination therapies

The market is witnessing a surge in demand for combination therapies, driven by their enhanced efficacy and ability to target multiple pathways simultaneously. This trend is propelled by the growing understanding of the complex nature and the need for more comprehensive treatment approaches. Combination therapies offer synergistic benefits, improved patient outcomes, and are increasingly preferred by healthcare providers and patients alike, shaping the landscape of treatment strategies.

Restraint:

Side effects of treatments

Corticosteroids may cause weight gain, mood swings, and increased risk of infection. Immunoglobulins can lead to allergic reactions or headaches. Splenectomy poses risks of infection due to reduced immune function and increases the risk of blood clots. Monitoring for these side effects and managing them appropriately is crucial in the treatment of thrombocytopenic purpura. Thus, in the market, treatments like corticosteroids, immunoglobulins, and splenectomy can have side effects.

Opportunity:

Advances in treatment options

Novel therapies such as thrombopoietin receptor agonists (TPO-RAs) have emerged as effective agents for increasing platelet counts in ITP patients. Additionally, immunomodulatory drugs like rituximab and fostamatinib have shown promise in managing refractory cases. These developments reflect a growing understanding of ITP's pathophysiology and highlight the evolving landscape of targeted therapies for this hematologic disorder. Hence, these are the factors driving the growth of the market.

Threat:

High cost of treatment

Patients often struggle with the financial burden of therapies, including immunoglobulins, corticosteroids, and splenectomy. These expenses can deter individuals from seeking necessary medical care and adhering to treatment plans. Additionally, research and development costs for innovative therapies contribute to the overall high cost of managing thrombocytopenic purpura, posing a barrier to accessible healthcare for affected individuals.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Thrombocytopenic Purpura Therapeutics Market. Lockdowns and healthcare priorities diverted focus from non-emergency conditions, affecting diagnosis and treatment. Supply chain disruptions led to shortages of critical medications, impacting patient care and treatment outcomes. Clinical trials were also delayed, hindering the development of new therapies. However, increased awareness of healthcare preparedness and telemedicine adoption could drive innovation and resilience in managing Thrombocytopenic Purpura in the post-pandemic era.

The rituximab segment is expected to be the largest during the forecast period

The rituximab segment is expected to be the largest during the forecast period. Rituximab, a monoclonal antibody targeting CD20 on B cells, has emerged as a promising therapy for thrombocytopenic purpura (ITP). In the therapeutics market, its role lies in modulating immune response, particularly in refractory or relapsed cases where conventional treatments fail. Its efficacy in increasing platelet counts and reducing bleeding episodes has bolstered its adoption, contributing significantly to the evolving landscape of ITP management.

The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period

The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period. They play a crucial role in the market by providing specialized care and procedures such as platelet transfusions and splenectomies. These centers offer a convenient and efficient setting for patients to receive treatment, contributing to improved patient outcomes and satisfaction. With advanced technologies and skilled medical professionals,

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The market in the region is characterized by a diverse range of treatment options, including corticosteroids, intravenous immunoglobulins, and thrombopoietin receptor agonists. This market is driven by increasing awareness, advancements in medical technology, and a growing patient population. Additionally, ongoing research and development efforts contribute to the expansion of treatment modalities and improved outcomes for individuals in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Awareness and its treatment options has increased among healthcare professionals and patients, leading to early diagnosis and treatment. Pharmaceutical companies are collaborating with healthcare providers and research institutions in the region to develop and commercialize new treatments. Continuous research and development efforts aimed at improving treatment efficacy and safety are expected to further drive market growth in the region.

Key players in the market

Some of the key players in Idiopathic Thrombocytopenic Purpura Therapeutics market include Novartis, Pfizer, Sanofi, Amgen Inc., Johnson & Johnson, Takeda Pharmaceutical Company, GlaxoSmithKline, AbbVie, Teva Pharmaceutical Industries, Merck & Co., Bayer, Vertex Pharmaceuticals, FUJIFILM Holdings Corporation, Olympus Corporation, F. Hoffmann-La Roche Ltd, Medtronic, Eli Lilly and Company, GrifolsBiologicals and Sun Pharmaceutical Industries Ltd.

Key Developments:

In January 2020, Novartis in association with The ITP Support Association announced the launch of ITP Pocket Log, designed to help people manage and track their ITP on the move, which is available on Google Play and Apple App Store.

In January 2019, GrifolsBiologicals Inc. announced that it has entered into a license agreement with the US-based biotechnology company Rigel Pharmaceuticals to commercialize fostamatinib disodium hexahydrate in all potential future indications in Europe and Turkey.

Products Covered:

• Anti-D Immunoglobulins
• Corticosteroids
• Intravenous Immunoglobulin (IVIG)
• Thrombopoietin Receptor Agonists (TPO-RA)
• Other Products

Treatment Types Covered:

• Splenectomy
• Rituximab
• Immunosuppressants
• Other Treatment Types

Mode of Administrations Covered:

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Distribution Channels Covered:

• Pharmaceutical Companies
• Distributors
• Retail Pharmacies
• Online Pharmacies

End Users Covered:

• Ambulatory Surgical Centers
• Hospitals
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product

• 5.1 Introduction
• 5.2 Anti-D Immunoglobulins
• 5.3 Corticosteroids
• 5.4 Intravenous Immunoglobulin (IVIG)
• 5.5 Thrombopoietin Receptor Agonists (TPO-RA)
• 5.6 Other Products

6 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Treatment Type

• 6.1 Introduction
• 6.2 Splenectomy
• 6.3 Rituximab
• 6.4 Immunosuppressants
• 6.5 Other Treatment Types

7 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Mode of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Subcutaneous
• 7.5 Intramuscular

8 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Pharmaceutical Companies
• 8.3 Distributors
• 8.4 Retail Pharmacies
• 8.5 Online Pharmacies

9 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By End User

• 9.1 Introduction
• 9.2 Ambulatory Surgical Centers
• 9.3 Hospitals
• 9.4 Clinics
• 9.5 Other End Users

10 Global Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Novartis
• 12.2 Pfizer
• 12.3 Sanofi
• 12.4 Amgen Inc.
• 12.5 Johnson & Johnson
• 12.6 Takeda Pharmaceutical Company
• 12.7 GlaxoSmithKline
• 12.8 AbbVie
• 12.9 Teva Pharmaceutical Industries
• 12.10 Merck & Co.
• 12.11 Bayer
• 12.12 Vertex Pharmaceuticals
• 12.13 FUJIFILM Holdings Corporation
• 12.14 Olympus Corporation
• 12.15 F. Hoffmann-La Roche Ltd
• 12.16 Medtronic
• 12.17 Eli Lilly and Company
• 12.18 GrifolsBiologicals
• 12.19 Sun Pharmaceutical Industries Ltd.